Clinical Trials on Melanoma Stage Iv in South Africa

Total 861 results

Immunocore Ltd

Active, not recruiting

Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma

Uveal Melanoma

United States, Canada, United Kingdom, Spain, France, Germany, Poland, Australia, Belgium, Italy, Netherlands, Russian Federation, Switzerland, Ukraine
GlaxoSmithKline

Completed

A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma

Cancer

Australia, Spain, United States, Germany, Poland, Italy, Canada, Ireland, Hungary, Russian Federation, Netherlands, France
Synta Pharmaceuticals Corp.

Terminated

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

Melanoma

United States, Spain, Canada, Australia, Germany, Puerto Rico, Romania, United Kingdom
City of Hope Medical Center
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Completed

Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer

Stage IV Breast Cancer | Estrogen Receptor Negative | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Negative | Progesterone Receptor Positive | Triple-Negative Breast Carcinoma

United States
Melanoma and Skin Cancer Trials Limited
Monash University; University of Sydney; The University of Queensland

Active, not recruiting

Melanoma Surveillance Photography (MSP) to Improve Early Detection of Melanoma in Ultra-high and High Risk Patients (IMAGE)

Melanoma | Skin Cancer | Anxiety and Fear

Australia
Incyte Corporation

Active, not recruiting

Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies

Melanoma

United States, Australia
Bristol-Myers Squibb

Completed

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Melanoma

France, Canada, United States, Germany, Australia, Russian Federation, Spain, Italy, Netherlands, Poland, Denmark, Israel, United Kingdom
Regeneron Pharmaceuticals

Recruiting

Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma

Melanoma

United States, Spain, Germany, Mexico, Turkey, Canada, Austria, Netherlands, United Kingdom, Italy, Georgia, France, Brazil, Romania, Czechia, Argentina, Australia, Ireland, Chile, Hungary, South Africa, Belgium, Poland, Peru
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Positive | HER2/Neu Negative | Progesterone Receptor Positive | Elevated CA15-3 or CEA or CA27-29

United States, Puerto Rico, Guam
Western Sydney Local Health District
University of Western Sydney

Recruiting

Liver Toxicity in Lung Cancer Patients Treated With Immune-checkpoint Inhibitors.

Hepatitis | Lung Cancer, Non-small Cell | Lung Cancer Stage IV

Australia
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Completed

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer

Stage IV Colorectal Cancer AJCC v7 | Stage IVA Colorectal Cancer AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Rectal Adenocarcinoma | Colon Adenocarcinoma | Stage III Colorectal Cancer AJCC v7 | Stage IIIA Colorectal Cancer AJCC v7 | Stage IIIB Colorectal Cancer AJCC v7 | Stage IIIC Colorectal Cancer...

United States
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
Bristol-Myers Squibb

Active, not recruiting

A Study to Assess Adjuvant Immunotherapy With Nivolumab Plus Relatlimab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma (RELATIVITY-098)

Melanoma

United States, Italy, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Czechia, Denmark, Finland, France, Germany, Greece, Israel, Mexico, Norway, Romania, Spain, Sweden, Switzerland, United Kingdom
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

Melanoma

Canada, United States, Australia, Belgium, Brazil, Chile, France, Germany, Israel, Italy, Japan, Poland, South Africa, Spain, Switzerland, United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery

Recurrent Colon Carcinoma | Recurrent Rectal Carcinoma | Rectal Adenocarcinoma | Colon Adenocarcinoma | ERBB2 Gene Amplification | Stage III Colon Cancer AJCC v7 | Stage III Rectal Cancer AJCC v7 | Stage IIIA Colon Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Colon Cancer AJCC v7 | Stage... and other conditions

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery

Desmoplastic Melanoma

United States
Bristol-Myers Squibb

Completed

An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV Melanoma (CheckMate 915)

Melanoma

Belgium, Brazil, United States, Canada, Spain, Greece, France, United Kingdom, Australia, Italy, Austria, Switzerland, Germany, Israel, Russian Federation, Romania, Czechia, Poland, New Zealand
Saint John's Cancer Institute
National Cancer Institute (NCI); National Institutes of Health (NIH)

Completed

Multicenter Selective Lymphadenectomy Trial II (MSLT-II)

Melanoma

United States, Australia, Italy, Spain, Canada, Netherlands, Germany, Finland, Israel, Sweden, Switzerland, United Kingdom
Bristol-Myers Squibb
Nektar Therapeutics

Completed

A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma

Melanoma

Canada, Australia, France, Italy, Brazil, United States, Argentina, Austria, Belgium, Chile, Czechia, Finland, Germany, Greece, Ireland, Israel, Mexico, Netherlands, New Zealand, Poland, Portugal, Romania, Russian Federation, Spain, Sweden and more
Bristol-Myers Squibb

Active, not recruiting

A Study of Relatlimab Plus Nivolumab Versus Nivolumab Alone in Participants With Advanced Melanoma (RELATIVITY-047)

Melanoma

Italy, United States, Germany, Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, Colombia, Denmark, Finland, France, Greece, Israel, Mexico, New Zealand, Norway, Poland, Romania, Russian Federation, Spain, Sweden, United Kingdom
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd

Active, not recruiting

Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma (CheckMate 238)

Melanoma

Argentina, United States, Australia, Austria, Belgium, Canada, Czechia, Finland, France, Greece, Hungary, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Norway, Poland, Romania, South Africa, Spain, Sweden, Switzerland, Taiwan, United Kingdom
National Cancer Institute (NCI)

Recruiting

Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Metastatic Colon Adenocarcinoma | Metastatic Rectal Adenocarcinoma | Stage III Colon Cancer AJCC v8 | Stage III Rectal Cancer AJCC v8 | Stage IV Colon Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Unresectable Colon Adenocarcinoma | Unresectable Rectal Adenocarcinoma

United States, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin Lymphoma

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States, Canada, Israel, Australia, Puerto Rico
Bayer
Amgen

Completed

A Treatment Combination for Patients With Unresectable Stage III or Stage IV Melanoma

Melanoma

United States, Canada, Germany, France, United Kingdom, Australia, Netherlands
GlaxoSmithKline

Terminated

A Phase III Study to Test the Benefit of a New Kind of Anti-cancer Treatment in Patients With Melanoma, After Surgical Removal of Their Tumor

Melanoma

United States, Australia, Spain, Taiwan, Bulgaria, Estonia, Germany, Belgium, France, Sweden, Israel, Poland, Italy, Czechia, Switzerland, Korea, Republic of, Ireland, Canada, Argentina, Netherlands, Russian Federation, Ukraine, Aus... and more
Novartis Pharmaceuticals

Completed

Dabrafenib With Trametinib in the Adjuvant Treatment of High-risk BRAF V600 Mutation-positive Melanoma (COMBI-AD). (COMBI-AD)

Melanoma

United States, Belgium, Canada, Spain, United Kingdom, Netherlands, Argentina, Australia, Austria, Brazil, Czechia, Denmark, France, Germany, Greece, Israel, Italy, Japan, New Zealand, Norway, Poland, Russian Federation, Sweden, Switz... and more
National Cancer Institute (NCI)

Terminated

Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma

Epithelioid Mesothelioma | Sarcomatoid Mesothelioma | Stage IV Pleural Mesothelioma | Recurrent Malignant Mesothelioma | Stage II Pleural Mesothelioma | Stage III Pleural Mesothelioma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Chemotherapy Toxicity On Quality of Life in Older Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer

Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC v6 and v7 | Stage II Ovarian Cancer AJCC v6 and v7 | Stage IIA Fallopian Tube Cancer AJCC v6 and v7 | Stage IIB Fallopian... and other conditions

United States
National Cancer Institute (NCI)

Completed

Nivolumab in Treating Patients With Recurrent and/or Metastatic Nasopharyngeal Cancer

Recurrent Nasopharynx Carcinoma | Stage III Nasopharyngeal Carcinoma AJCC v7 | Stage IV Nasopharyngeal Carcinoma AJCC v7 | Stage IVA Nasopharyngeal Carcinoma AJCC v7 | Stage IVB Nasopharyngeal Carcinoma AJCC v7 | Stage IVC Nasopharyngeal Carcinoma AJCC v7 | Nasopharyngeal Nonkeratinizing Carcinoma

United States, Singapore, China
National Cancer Institute (NCI)

Active, not recruiting

Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction

Metastatic Urothelial Carcinoma | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Locally Advanced Urothelial Carcinoma | Recurrent Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Advanced Urothelial Carcinoma

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Unknown

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Fatigue | Anxiety | Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Stage I Ovarian Cancer AJCC v6 and v7 | Stage IA Fallopian Tube Cancer AJCC v6 and v7 | Stage IB Fallopian Tube Cancer AJCC v6 and v7 | Stage IC Fallopian Tube Cancer AJCC... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Stage IV Colon Cancer | Stage IV Rectal Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer

United States
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma

United States
Gilead Sciences

Recruiting

Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Metastatic Breast Cancer Who Have Received Endocrine Therapy (ASCENT-07)

Stage IV Breast Cancer | Locally Advanced or Unresectable Metastatic Breast Cancer

Taiwan, Korea, Republic of, Australia, Greece, Spain, United States, United Kingdom, France, Israel, Malaysia, Japan, Belgium, Poland, China, Germany, Czechia, Singapore, Hungary, Brazil, Italy, South Africa, Portugal, Argentina, Hong... and more
Mythic Therapeutics

Recruiting

Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer | NSCLC | Advanced Non-Small Cell Lung Cancer | NSCLC Stage IV | NSCLC Stage IIIB | Advanced Non-Small Cell Squamous Lung Cancer | Advanced Non-Small Cell Non-Squamous Lung Cancer

United States, Australia, Korea, Republic of, United Kingdom
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers

Metastatic Small Intestinal Adenocarcinoma | Stage III Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIA Small Intestinal Adenocarcinoma AJCC v8 | Stage IIIB Small Intestinal Adenocarcinoma AJCC v8 | Stage IV Small Intestinal Adenocarcinoma AJCC v8

United States
National Cancer Institute (NCI)

Active, not recruiting

Olaparib and Ramucirumab in Treating Patients With Metastatic or Locally Recurrent Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery

Recurrent Esophageal Carcinoma | Recurrent Gastric Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Unresectable Gastroesophageal Junction Adenocarcinoma | Metastatic Esophageal Carcinoma | Metastatic Gastric Carcinoma | Stage IV Esophageal Cancer AJCC v7 | Stage IV Gastric Cancer... and other conditions

United States
National Cancer Institute (NCI)
Radiation Therapy Oncology Group

Completed

Bevacizumab, Cisplatin, Radiation Therapy, and Fluorouracil in Treating Patients With Stage IIB, Stage III, Stage IVA, or Stage IVB Nasopharyngeal Cancer

Stage IV Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage IV Nasopharyngeal Undifferentiated Carcinoma AJCC v7 | Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage III Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 | Stage III Nasopharyngeal...

United States, Canada
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
NRG Oncology
National Cancer Institute (NCI)

Recruiting

Letrozole With or Without Paclitaxel and Carboplatin in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Stage III Fallopian Tube Cancer AJCC v8 | Stage III Ovarian Cancer AJCC v8 | Stage III Primary Peritoneal Cancer AJCC v8 | Stage IV Fallopian Tube Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage IV Primary Peritoneal Cancer AJCC v8 | Stage II Fallopian Tube Cancer AJCC v8 | Stage II Ovarian... and other conditions

United States, Canada, Korea, Republic of, Puerto Rico, Ireland
National Cancer Institute (NCI)

Recruiting

Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial)

Stage III Intrahepatic Cholangiocarcinoma AJCC v8 | Recurrent Gallbladder Carcinoma | Unresectable Gallbladder Carcinoma | Stage III Hilar Cholangiocarcinoma AJCC v8 | Stage IV Hilar Cholangiocarcinoma AJCC v8 | Stage IV Intrahepatic Cholangiocarcinoma AJCC v8 | Stage IV Distal Bile Duct Cancer... and other conditions

United States
Merck Sharp & Dohme LLC

Active, not recruiting

Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)

Melanoma

United States, Australia, France, Israel, Italy, Switzerland
Amgen
Merck Sharp & Dohme LLC

Completed

Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).

Melanoma

United States, Canada, Spain, France, Australia, Greece, Italy, United Kingdom, Germany, Netherlands, Poland
National Cancer Institute (NCI)

Active, not recruiting

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer

Combined Hepatocellular Carcinoma and Cholangiocarcinoma | Stage III Liver Cancer | Stage IV Liver Cancer

United States
Southwest Oncology Group
Patient-Centered Outcomes Research Institute; National Cancer Institute (NCI)

Completed

S1415CD, Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER) (TrACER)

Stage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Febrile Neutropenia | Stage 0 Breast Cancer | Stage IV Non-Small Cell Lung Cancer | Stage IV Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast... and other conditions

United States, Puerto Rico
Merck Sharp & Dohme LLC

Recruiting

Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)

Melanoma

Spain, Poland, United States, Australia, France, Israel, Italy, South Africa, Switzerland, Chile, Greece, Colombia, Hungary, Argentina
National Cancer Institute (NCI)

Terminated

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Recurrent Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v7 | Stage IV Renal Cell Cancer AJCC v7 | Metastatic Kidney Carcinoma

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Suspended

Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients With Recurrent Stage IIIC-IV Breast Cancer

Invasive Breast Carcinoma | HER2/Neu Negative | Stage IV Breast Cancer AJCC v6 and v7 | Stage IIIC Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma

Advanced Merkel Cell Carcinoma | Metastatic Merkel Cell Carcinoma | Pathologic Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage III Cutaneous Merkel Cell Carcinoma AJCC v8 | Clinical Stage IV Cutaneous Merkel Cell Carcinoma AJCC v8 | Pathologic Stage IIIA Cutaneous Merkel... and other conditions

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men With Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy (CASPAR)

Castration-Resistant Prostate Carcinoma | Stage IV Prostate Cancer AJCC v8 | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States

Clinical Trials on Melanoma Stage Iv in South Africa

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Croatia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations